Testing a combination of five medications for children with difficult-to-treat blood cancers

This trial is testing whether ruxolitinib—a newer medication—combined with four other chemotherapy drugs can help children and young adults whose blood cancers (leukemia or lymphoma) have come back or stopped responding to standard treatment. The trial focuses on patients whose cancers have specific genetic changes that make them good candidates for this particular combination. The goal is to see if this targeted approach is both safe and effective.

Children whose blood cancers return or become resistant to initial treatment face very poor outcomes with standard approaches. This medication targets the specific genetic pathways that drive some of these resistant cancers, offering hope that a more personalized, targeted strategy could improve survival and reduce side effects compared to one-size-fits-all chemotherapy.